Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20819729 | 0.84 | LPL (0.38) | LPLLIPGEGFRTHRATHRB | |
| SCHEMBL29704024 | 0.83 | TAAR1 (0.38) | LPLLIPGEGFR | |
| SCHEMBL14658943 | 0.83 | TAAR1 (0.38) | LPLLIPGEGFR | |
| SCHEMBL22748290 | 0.83 | LPL (0.40) | LPLLIPGEGFRTHRATHRB | |
| SCHEMBL14659201 | 0.81 | ALOX5AP (0.34) | — | |
| SCHEMBL29563585 | 0.81 | ALOX5AP (0.34) | — | |
| SCHEMBL29652912 | 0.80 | DGAT1 (0.40) | L3MBTL1 | |
| SCHEMBL17258894 | 0.80 | DGAT1 (0.40) | L3MBTL1 | |
| SCHEMBL16637155 | 0.80 | LPL (0.36) | LPLLIPG | |
| SCHEMBL18805560 | 0.76 | JAK2 (0.36) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11713315-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230192710-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11667637-B2 | Fused imidazo-piperidine JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2017079205-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | LPL 4393/4885LIPG 3569/4885EGFR 238/4885 |
| US-20230192710-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | JAK2, JAK1, JAK3 | LPL 4862/4885LIPG 4075/4885EGFR 725/4885 |
| US-11667637-B2 | Fused imidazo-piperidine JAK inhibitors | JAK2, JAK1, JAK3 | LPL 4754/4885LIPG 4273/4885EGFR 310/4885 |
| US-11713315-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | JAK1, JAK2, JAK3 | LPL 4770/4885LIPG 3975/4885EGFR 170/4885 |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | JAK1, JAK2, JAK3 | LPL 4393/4885LIPG 3569/4885EGFR 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.